From Mechanism to Medicine

Our R&D pipeline follows a simple but powerful logic:

Understand the mechanism

Dissect how genome instability, DNA repair defects and 3D chromatin architecture drive aging, cancer and immune dysregulation.

Model the disease

Create highly tailored mouse models that mimic human pathologies, using tissue-specific and inducible systems to restrict mutations to defined cell types.

Map the molecular landscape

Apply multi-omics (genomics, transcriptomics, epigenomics, 3D epigenetics) and advanced imaging to capture what changes at the molecular and cellular level.

Design the therapeutic strategy

Use these insights to design targeted biological and mRNA-based drugs, and modern delivery systems that take therapies exactly where they are needed.

Prepare for translation

Build preclinical packages aligned with EMA/FDA expectations, and embed quality, safety and standardisation from day one.

Next-Generation Therapeutics: Biologicals & mRNA

A central focus of Genodis R&D is to develop a new class of targeted anti-inflammatory and immune-modulating drugs, with three clear advantages:

  • Precision: drugs delivered specifically to affected cells and tissues, reducing off-target effects
  • Flexibility: a single mRNA production platform can quickly generate multiple constructs by changing only the encoded sequence
  • Personalisation: mRNA constructs can be tailored to patient- or mutation-specific needs, opening real avenues for personalized medicine and rare disease treatments

Our R&D explores:

  • Targeted intracellular delivery of oligonucleotide compositions to modulate disease-relevant cell types
  • Synthetic nanocarriers carrying immunosuppressants to inflammatory foci, or used for immunotherapy
  • Manufacturing concepts where one production unit can generate a portfolio of mRNA products with shared workflows, equipment and operating conditions

These innovations are supported by a proactive IP strategy with high patentability potential in delivery methods and compositions.

Standards, Regulation & “Translation-Ready” Science

Our R&D is designed to be regulation-aware from the start.

Genodis works with regulatory experts to:

  • Seek early scientific advice from national authorities and the EMA
  • Align preclinical studies with intended clinical products (dose, regimen, formulation, route of administration)
  • Validate analytical methods for biodistribution, persistence and clearance of biological drugs and carriers
  • Incorporate quality frameworks (GMP, ISO 9001, EN-ISO 10993, etc.) and contribute to emerging industry standards for advanced therapeutics

The goal is simple: data and products that regulators recognise as robust, compliant and ready to move forward.